Biomeditsina va amaliyot jurnali, 2022 №5
Subject of the article
STUDY OF BLOOD GAS COMPOSITION AND CORRECTION OF TREATMENT IN PATIENTS WITH PULMONARY HYPERTENSION ON THE BACKGROUND OF CHRONIC HEART FAILURE AFTER COVID-19 (495-502)
Authors
Ibragimov Ulug’bek, Gadayev Abdugaffar, Turakulov Rustam, Abdukholikov Oybek.
Institution
Tashkent Medical Academy
Abstract
A number of literature reports on changes in the gas composition of the blood in patients with pulmonary hypertension, which developed on the basis of chronic heart failure. But the blood gases seen in this cohort of Covid-19 patients are not well understood. This article studied and analyzed in detail the blood gas content in patients with pulmonary hypertension, which developed against the background of chronic heart failure caused by Covid-19, before and after treatment with various components
Key words
Covid-19, chronic heart failure, pulmonary hypertension, eplerenone, empagliflozin, blood gase
Literature
Гадаев, А., Туракулов, Р., Пирматова, Н., & Эшонкулов, С. (2022). Особенности течения хронической сердечной недостаточностью, перенесших Covid-19 по данным ретроспективного анализа историй болезни. Scientific Collection «InterConf+», (22(113), 338–348. 2. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) // Сердечная недостаточность. - 2013. - № 7(81). - С. 379-472.. 3. Пирматова Н.В., Гадаев А.Г., Рахимова М.Э., Гадаева Н.А. ндотелиальная дисфункция у больных хронической сердечной недостаточностью, перенесших и не болевших covid- 19, Терапевтический вестник Узбекистана, 2021, №2, 28-32-б. 4. Токмачев Р.Е., Мухортова М.С., Будневский А.В., Токмачев Е.В., Овсянников Е.С. Коморбидность хронической сердечной недостаточности и хронической обструктивной болезни легких: особенности патогенеза, клиники и диагностики. Кардиоваскулярная терапия и профилактика. 2018;17(6):62-68. 5. Alfonso F., Dutary J., Paulo M., Gonzalo N., Pйrez-Vizcayno M.J. et al. Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis // Heart. 2012. Vol. 98(16). P. 1213–1220. 6. Castiglione L, Droppa M. Pulmonary Hypertension and COVID-19. Hamostaseologie. 2022 Aug;42(4):230-238. doi: 10.1055/a-1661-0240. Epub 2021 Dec 21. PMID: 34933375. 7. Guazzi M., Arena R., Halle M. et al. 2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations. Circulation 2016; 133: e694-e711. 8. Han Y, Cho Y‐E, Ayon R, Guo R, Guo R, Youssef KD, Pan M, Dai A, Yuan JXJ, Makino A. SGLT inhibitors attenuate NO‐dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol‐Lung Cell Mol Physio. 2015;309(9):L1027–L36. 9. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM,Tang F, Lamba S, Bhatt K, Brush J, Civitello A, Gordon R, Jonsson O, Lampert B, Pelzel J, Kosiborod MN. Empagliflozin effects on pulmonary artery pressure in patients with heart failure. Circulation. 2021;143(17):1673– 86.